Cargando…
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poor response to chemotherapy and dismal survival. Identification of effective strategies to target PTCL biology represents an urgent need. Here we report that PTCL are sensitive to transcription-targeting drugs, and, in particular, to...
Autores principales: | Cayrol, Florencia, Praditsuktavorn, Pannee, Fernando, Tharu M., Kwiatkowski, Nicholas, Marullo, Rosella, Calvo-Vidal, M. Nieves, Phillip, Jude, Pera, Benet, Yang, Shao Ning, Takpradit, Kaipol, Roman, Lidia, Gaudiano, Marcello, Crescenzo, Ramona, Ruan, Jia, Inghirami, Giorgio, Zhang, Tinghu, Cremaschi, Graciela, Gray, Nathanael S., Cerchietti, Leandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290269/ https://www.ncbi.nlm.nih.gov/pubmed/28134252 http://dx.doi.org/10.1038/ncomms14290 |
Ejemplares similares
-
Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
por: Cayrol, Florencia, et al.
Publicado: (2017) -
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway
por: Pera, Benet, et al.
Publicado: (2018) -
Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma
por: Gao, Yang, et al.
Publicado: (2022) -
Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation
por: Ma, Xinqi, et al.
Publicado: (2018) -
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients
por: Pera, Benet, et al.
Publicado: (2016)